Themis Medicare Limited

Operating profitability is structurally weak and unstable: overall OPM is 0.12%, with quarterly swings from -60.28% (Jun 2026) to 10.86% (Dec 2025); verify which quarters represent core operations vs one-time items, and whether this volatility reflects cost-control challenges or transient supply/production issues.

Return on equity of 0.28% is critically low; despite regular dividend payments, capital is generating minimal returns and raising questions about dividend sustainability and capital deployment strategy.

June 2026 shows net profit of ₹24.61–28.74 Cr but negative operating margin of -60.28%, indicating heavy reliance on non-operating income; verify composition of earnings and whether the operating business is structurally cash-generative.

Stock has underperformed 8.83% over 12 months and PE multiple of 869.97 reflects distress pricing; verify if this reflects temporary headwinds or structural weakness in the company's served segments and competitive position.

Latest quarter (Jun 2026) revenue reached ₹86.96 Cr (highest in dataset) with net profit ₹24.61–28.74 Cr; verify whether this reflects operational inflection or one-time items, and if momentum sustains.

Consistent dividend payouts (2022–2025) signal recurring cash generation; verify cash-conversion quality and whether dividends are funded from operating cash flow vs equity drawdown.

Verify exposure to high-growth segments (specialty pharma, biosimilars, exports) vs commodity generics—if Themis serves expanding therapeutic areas or geographies, this could unlock volume and pricing upside beyond the current ₹77–87 Cr quarterly base.